Volume 8
Variant CJD

Terms of Reference, Committee Members and Report Volumes ix
A note on the footnotes x

1 Introduction 1

2 History of CJD surveillance up to 1990 3

Introduction 3
Surveillance in the UK before the emergence of BSE 3
Concern about exposure to scrapie and risk of CJD 4
The retrospective study (1970–79) 5
The prospective study (1980–84) 5
Amalgamated study of CJD (1970–84) 6
Human growth hormone-derived CJD 7
BSE discovery and the recommendations for CJD surveillance 8
Southwood recommendations with respect to CJD surveillance 9
Government’s response to Southwood recommendations with respect to CJD surveillance 10
Tyrrell recommendations with respect to CJD surveillance 11

3 Establishment of the CJD Surveillance Unit 13

Introduction 13
Establishment 13
Terms of reference 13
Funding and resources 14
Review of the CJDSU by the Allen Committee 14
4 April 1991 15
1 July 1991 16
22 February 1993 16
19 July 1995 16
Public Health Laboratory Service involvement 17
PHLS and CJD surveillance 18
Second request for PHLS involvement in CJD surveillance 20
What could the PHLS have contributed to CJD surveillance? 22
Paediatric surveillance and access to medical registers 22
Development and administration of the questionnaire 23
Dissemination of information 23
Facilitating links with clinicians other than neurologists 24
4 Work of the CJD Surveillance Unit

Introduction 25
Retrospective study of CJD 25
Prospective study of CJD 26
Development of the questionnaire 27
Development of the statistical analysis – epidemiology 27
Results of the surveillance (1991–95) 27
  Clinical surveillance 29
  Case-control analysis 30
  Neuropathological validation 30
  Genetic studies 31
  European surveillance 32
Fifth Annual Report (1996) 32

5 Emergence of variant CJD

Introduction 33
Chronological account of the emergence of vCJD 33
  1989 33
  ‘The first farmer’ – August 1992 34
  ‘The second farmer’ – July 1993 36
  First young suspect case of CJD (Case A) – January 1994 37
  ‘The third farmer’ – December 1994 38
  Second young suspect case of CJD (Case D) – May 1995
    (later confirmed as vCJD) 41
  Third young suspect case of CJD (Case E) – August 1995
    (later confirmed as vCJD) 42
  The fourth farmer – September 1995 44
Evolution of knowledge leading to the identification of new variant CJD
and the hypothesis of causal link with BSE between late 1995
and early March 1996 47
  Results of statistical analysis of CJD in young cases 57
  Dr Will’s presentation at the Parliamentary Food and Health Forum on
    20 February 1996 57
  Dr Will’s comments on an MLC briefing paper on 23 February 1996 58
  Further developments in knowledge from late February 1996 59
Relevant events after 20 March 1996 65
  Update on cases of CJD in farmers 67
  Update on suspect cases of CJD in teenagers 67
  Future incidence of vCJD 68
Discussion on the work of the CJD Surveillance Unit (CJDSU) 68
  Could vCJD have been identified earlier? 69
  Could PHLS have been usefully involved in surveillance? 71
Was there adequate communication of information to the Department of Health? 72
Was involvement of the CJDSU in the public debate about the safety of beef appropriate? 73
Is a link between BSE and vCJD established? 74
Some observations about vCJD that call for explanation 74
  Why does vCJD seem to be a disease of young people? 74
  Is there evidence of clustering of vCJD cases? 76
  Why have all cases of vCJD tested to date been homozygous for methionine at codon 129 on the prion protein gene? 77
  Why have all patients with vCJD so far investigated shown signs of high levels of infectivity in tonsils and other parts of the lymphoreticular system, whereas cases of sporadic and iatrogenic CJD have not? 78
  Is occupation a risk factor in vCJD? 78
  How many people are likely to succumb to vCJD? 79

Annex to Chapter 5: Information on patients under 50 referred to the CJDSU before 20 March 1996 81

6 Diagnosis, treatment and care of vCJD patients 82
Introduction 82
Symptoms of vCJD 82
Diagnosis of vCJD by the medical profession 83
  General practitioners 83
  Psychiatrists 83
  Neurologists 85
Tests performed 87
  Blood tests 88
  Genetic analysis 88
  Lumbar puncture 88
  Computerised axial tomography (CT) scan 89
  Electroencephalogram (EEG) 89
  Magnetic resonance imaging (MRI) 89
  Biopsies 90
    Brain biopsy 90
    Tonsil biopsy 90
  Clinical history – personal and family 91
Treatment and care of vCJD patients 91
  Progression of the disease and stages of care 92
  Initial care and treatment by the General Practitioner (GP) 92
  Referral of patient to a psychiatrist or a neurologist 93
    Psychiatrists 93
Neurologists 94
Admission to hospital for testing by the psychiatrist and/or neurologist 94
Communication and information 95
Involvement of the national Creutzfeldt-Jakob Disease Surveillance Unit 97
Treatment and care of the patient following diagnosis of probable vCJD 97
Caring for patients at home 97
Provision of aids and equipment 98
The role of social services 100
The role of other healthcare professionals 101
Care of patients in hospitals, hospices, disabled units and other specialist hospitals 102
Financial costs to the families 103
Perceptions of the risk to health care professionals 104
Post-mortem and burial/cremation issues 104
Death certification 106
Registration of deaths: England and Wales 106
Inquests and fatal accident inquiries 109
Inquests in England and Wales 109
Inquests in Northern Ireland 112
Fatal accidents inquiries in Scotland 113
Organisations set up for the families of vCJD victims 114
CJD Support Network 114
Human BSE Foundation 114
Discussion of diagnosis, treatment and care of vCJD victims 115

Annex 1: CJDSU questionnaires 117

Annex 2: Summary tables on the clinical investigative and pathological data on suspect or confirmed cases of CJD aged less than 50 years 187

List of acronyms 197

Who’s who 199

Index 205

List of figures and tables
Table 4.1: Development of the CJD questionnaire 28
Table 4.2: Deaths from Creutzfeldt-Jakob Disease 29
Table 5.1: Number of definite and probable cases of vCJD since 1995 68
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 5.1</td>
<td>Geographical distribution of places of residence of vCJD cases at onset of symptoms</td>
<td>77</td>
</tr>
<tr>
<td>Figure 5.2</td>
<td>Cases of vCJD by date of onset, notification, death and confirmation</td>
<td>80</td>
</tr>
</tbody>
</table>